Clinical Trial

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

Study acronym: STAR-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia
Protocol Amendment History 5 changes
notable Trial sites expanded: 12 -> 16 locations 2026-07-30
notable Trial sites expanded: 7 -> 12 locations 2026-06-27
notable Primary completion pushed: 2027-04-22 -> 2027-07-29 2026-06-27
minor Completion pushed: 2027-04-22 -> 2027-07-29 2026-06-27
notable Trial sites expanded: 2 -> 7 locations 2026-05-02
Trial Details
NCT Number NCT07467993
Lead Sponsor Novartis Pharmaceuticals
Conditions Schizophrenia
Enrollment 142 participants
Start Date 2026-03-16
Primary Completion 2027-07-29 (estimated)
Study Completion 2027-07-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-29